Nurix Therapeutics to Participate in Upcoming Investor Conferences
31 Agosto 2023 - 5:01PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with hematologic malignancies and
solid tumors, today announced that Arthur T. Sands, M.D., Ph.D.,
Nurix’s president and chief executive officer will participate in
the following conferences in September:
- Wells Fargo Healthcare
ConferenceFireside chat: Thursday, September 7, 3:00 –
3:45 p.m. ET
- Baird Global Healthcare
ConferenceFireside chat: Tuesday, September 12, 12:15 –
12:45 p.m. ET
The events will be webcast live and may be accessed via a link
in the Investors section of the Nurix website under Events and
Presentations. Archived copies of the webcasts will be available on
the Nurix website for approximately 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
medicines based on the modulation of cellular protein levels as a
novel treatment approach for cancer and other challenging diseases.
Leveraging extensive expertise in E3 ligases together with
proprietary DNA-encoded libraries, Nurix has built DELigase, an
integrated discovery platform, to identify and advance novel drug
candidates targeting E3 ligases, a broad class of enzymes that can
modulate proteins within the cell. Nurix’s drug discovery approach
is to either harness or inhibit the natural function of E3 ligases
within the ubiquitin-proteasome system to selectively decrease or
increase cellular protein levels. Nurix’s wholly owned, clinical
stage pipeline includes targeted protein degraders of Bruton’s
tyrosine kinase, a B-cell signaling protein, and inhibitors of
Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that
regulates activation of multiple immune cell types including T cell
and NK cells. Nurix is headquartered in San Francisco, California.
For additional information visit http://www.nurixtx.com.
Contacts:
InvestorsSilinda NeouNurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Nurix Therapeutics (NASDAQ:NRIX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024